Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 3/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7940030 | 0.84 | HDAC1 (0.50) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7487824 | 0.84 | TBXA2R (0.50) | CXCR1CXCR2CCR2PTGES2ACLY | |
| SCHEMBL7496445 | 0.84 | ACLY (0.52) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL3709166 | 0.84 | CXCR2 (0.63) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7490402 | 0.84 | GPR27 (0.51) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7491182 | 0.83 | GPR27 (0.51) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7493701 | 0.83 | STAT3 (0.51) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7555940 | 0.81 | SLC22A12 (0.52) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7487915 | 0.81 | CXCR1 (0.45) | CXCR1CXCR2CCR2PTGES2GPR27 | |
| SCHEMBL7553684 | 0.81 | MEN1 (0.57) | CCR2ACLYKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0896531-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0896531-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-17 | — | — | EP | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997029743-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR1 21/4885CXCR2 15/4885CCR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.